An interventional study of Text Messages in Influenza Vaccination, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-24.
Sponsored by Columbia University · Not applicable, Interventional, and Health services research
Influenza infection leads to on average 24,0000 deaths and 150,000 hospitalizations annually. While vaccination is the cornerstone of preventing influenza infection, vaccination coverage in adults is low with only 35% vaccinated by end of November. Latino adults have the lowest coverage rates. Text message reminders have been used successfully for improving influenza vaccination for children. This study will assess the use of text messaging to improve influenza vaccination coverage rates in a largely minority, publicly insured adult population.
2,215 studies on the registry are indexed under Influenza, Human; 164 are open to participants now.
This study's enrollment of 7,250 is above the median of 239 across 1,854 interventional studies indexed under Influenza, Human.
Browse Influenza, Human studies →Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.
Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Text Message
Behavioral: Text Messages
Timeliness of vaccination
Days from start of intervention to vaccination
Time frame: 6 months
Receipt of influenza vaccine dose
Proportion of individuals in each group receiving an influenza dose by December 31, 2013
Time frame: 15 weeks
Receipt of Influenza vaccine dose, end of season
Proportion of individuals in each group receiving an influenza dose by March 31st, 2014
Time frame: 28 weeks
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Columbia University